<DOC>
	<DOCNO>NCT00542061</DOCNO>
	<brief_summary>The purpose study determine clinical effectiveness cost-effectiveness write expert advice GPs additional diagnostic , treatment , referral patient base half-yearly monitoring routine patient COPD ashtma persistent obstruction primary care base multicentre randomise nested clinical trial</brief_summary>
	<brief_title>Monitoring Asthma COPD Primary Care</brief_title>
	<detailed_description>In Netherlands , majority patient ( 60-80 % ) asthma COPD treat primary care , primarily General Practitioners ( GPs ) . In 1995 Regional Diagnostic Centre , Etten-Leur , The Netherlands ( also call SHL : Stichting Huisartsen Laboratorium ) start lung function monitoring service patient asthma COPD GPs region . The GP receive recommendation treatment , additional diagnostics referral patient base extensive anamnesis ( i.e . dyspnoea , symptom , smoke stage ) , measurement lung function , BMI . Moreover , general practitioner support Asthma/COPD nurse visit general practice half-yearly . Main research question study : Is write expert advice GPs additional diagnostic , treatment , referral patient base half-yearly monitoring patient COPD asthma persistent airway obstruction support AC nurse consultant relate less impaired health relate quality life ( HRQoL ) , less symptom well lung function patient compare usual care ? A multi-centre , single blind ( patient , lung function assistant , advisor , research team blind ) , parallel group study carry compare monitor intervention usual care 24 month . General practice allocate minimisation procedure participate patient general practice allocate treatment group ( nested design ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<criteria>The patient categorise asthmatic disease persistent airway obstruction COPD monitoring system SHL confirm recent lung function assessment ( FEV1/FVC &lt; 70 % BD FEV1 ≥ 50 % pred BD ) ( FEV1 &lt; 80 % predict BD ≥ 9 % reversibility ) The patient monitor AC service SHL . The GP patient willing participate trial . Written inform consent participant Patients treat primary pulmonologist Patients currently participate another respiratory intervention study When GP consider detrimental patient participate study Serious nonpulmonary disease ( diseasestages ) presume lead `` lose followup '' severity disease course ( like disease low survival rate mental deterioration ) Serious pulmonary disease effect bronchial symptom and/or lung function , e.g . sarcoidosis , lung cancer , lung fibrosis Illiteracy</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>COPD</keyword>
	<keyword>Asthma</keyword>
	<keyword>Lung function</keyword>
	<keyword>Monitoring</keyword>
	<keyword>Primary Care</keyword>
</DOC>